Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $1,006,625.12 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Insmed Trading Down 0.5 %

INSM stock opened at $72.87 on Thursday. The business’s 50-day moving average is $74.77 and its 200 day moving average is $51.39. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The stock has a market cap of $10.83 billion, a price-to-earnings ratio of -13.93 and a beta of 1.11. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. During the same quarter in the previous year, the company earned ($1.78) earnings per share. Insmed’s revenue was up 17.0% on a year-over-year basis. On average, sell-side analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of research reports. Bank of America restated a “buy” rating and set a $83.00 target price on shares of Insmed in a research report on Friday, July 5th. The Goldman Sachs Group upped their target price on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Guggenheim lifted their price target on Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Barclays boosted their price target on Insmed from $40.00 to $63.00 and gave the company an “overweight” rating in a report on Wednesday, May 29th. Finally, StockNews.com cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.19.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Darwin Global Management Ltd. acquired a new position in Insmed in the 2nd quarter valued at about $237,076,000. Capital International Investors purchased a new stake in shares of Insmed during the 1st quarter valued at approximately $43,973,000. Norges Bank acquired a new position in Insmed in the fourth quarter valued at approximately $45,029,000. Clearbridge Investments LLC purchased a new position in Insmed in the first quarter worth approximately $25,242,000. Finally, Vestal Point Capital LP purchased a new position in Insmed in the fourth quarter worth approximately $27,891,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.